Scilex Holding Stock Dividend/808CNT018

$0.00

0%
-
1D1W1MYTD1YMAX

About Scilex Holding Stock Dividend

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

Ticker

808CNT018

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jaisim Shah

Employees

105

Headquarters

Palo alto, United States

808CNT018 Metrics

BasicAdvanced
$212.72M
Market cap
-
P/E ratio
-$1.25
EPS
-
Beta
-
Dividend rate
$212.72M
$14.86
$0.90
930.51K
0.187
0.17
-11.86%
-121.73%
4.551
22.9%
-659.25%
25.66%

What the Analysts think about 808CNT018

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 3 analysts.
∞% upside
High $12.00
Low $4.00
$0.00
Current price
$6.83
Average price target

808CNT018 Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-159.7% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$13.4M
32.67%
Net income
$-21.4M
-39.72%
Profit margin
-159.7%
-54.56%

808CNT018 Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.29%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Actual
-$0.63
-$0.25
-
Expected
-$0.17
-$0.23
-$0.10
Surprise
263.46%
10.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Scilex Holding Stock Dividend stock?

Scilex Holding Stock Dividend (808CNT018) has a market cap of $212.72M as of April 18, 2024.

What is the P/E ratio for Scilex Holding Stock Dividend stock?

The price to earnings (P/E) ratio for Scilex Holding Stock Dividend (808CNT018) stock is 0 as of April 18, 2024.

Does Scilex Holding Stock Dividend stock pay dividends?

No, Scilex Holding Stock Dividend (808CNT018) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Scilex Holding Stock Dividend dividend payment date?

Scilex Holding Stock Dividend (808CNT018) stock does not pay dividends to its shareholders.

What is the beta indicator for Scilex Holding Stock Dividend?

Scilex Holding Stock Dividend (808CNT018) does not currently have a Beta indicator.

What is the Scilex Holding Stock Dividend stock price target?

The target price for Scilex Holding Stock Dividend (808CNT018) stock is $6.83, which is Infinity% above the current price of $0. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Scilex Holding Stock Dividend

Buy or sell Scilex Holding Stock Dividend

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing